Downstream Processing Featured Articles

  1. 'Patch on a Chip' under development by Axon Instruments 11/1/2000
    New fabrication method will allow thousands of simultaneous patch clamp recordings...
  2. Sanford-Burnham Research Projects Selected To Go To Space 11/29/2012

    We’re excited to announce recently that two of our research teams have won Space Florida’sInternational Space Station (ISS) Research Competition. Eight teams were selected from a pool of international applicants to send experiments to space in late 2013.

  3. Fragile X Makes Brain Cells Talk Too Much 2/20/2013

    The most common inherited form of mental retardation and autism, fragile X syndrome, turns some brain cells into chatterboxes, scientists at Washington University School of Medicine in St. Louis report. By Michael C. Purdy

  4. Saving Patients From The Needle Boosts Drug Delivery Company Revenues: Report 2/20/2013

    Led by needle-free delivery systems the advanced implantable/injectible drug delivery market reached revenues of $13.3 billion in 2012, according to their recently published report Injectable, Implantable and Needle-Free Drug Delivery Systems.

  5. Roche Invests In Stratos Genomics For Further Development Of The 'Sequencing By Expansion' (SBX) Method Applied To Single Molecule Nanopore Sequencing 6/26/2014

    Roche announced recently, it made a strategic investment in Stratos Genomics and entered into a research collaboration to support further development of their unique chemistry applied to single molecule sequencing of DNA fragments using protein nanopores.

  6. FDA Lifts Clinical Hold On Lpath's iSONEP 8/27/2012

    Lpath, Inc. (OTCQB: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported that the FDA has lifted the clinical hold on iSONEP™, Lpath's anti-S1P monoclonal antibody that is being developed as a potential treatment for wet AMD and possibly other ocular disorders.

  7. Population Genetics Validates GenomePooling For Cancer 7/31/2012

    Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.

  8. Designer Bacteria May Lead To Better Vaccines 1/15/2013

    Researchers at The University of Texas at Austin have developed a menu of 61 new strains of genetically engineered bacteria that may improve the efficacy of vaccines for diseases such as flu, pertussis, cholera and HPV.

  9. FDA Approval Pushes Novartis Into 21st Century Vaccine Development 6/18/2014

    In 2009, the world experienced a global threat in the form of H1N1. Despite a prompt response to the need for a vaccine in the United States, it was still not available until six months later and not enough doses were even produced to cover all Americans. During the year-long battle with the deadly virus, the CDC estimates between 8,870 and 18,300 people died due to H1N1-related complications. In the world of influenza vaccine production using chicken eggs, the response experienced during the H1N1 outbreak is not uncommon. Is this the best our industry can do? Novartis says NO.

  10. Refine Technology And Gallus BioPharmaceuticals To Collaborate On Continuous BioManufacturing 1/22/2013

    Refine Technology, LLC (Refine), the developer and worldwide supplier to the biotech industry of the ATF™ System, a best-in-class cell retention device, and Gallus BioPharmaceuticals, LLC (Gallus), the industry leading contract bulk biopharmaceuticals manufacturer, today announced a collaboration to optimize continuous cell culture processes.